Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanistic Studies of Psilocybin in Headache Disorders
NCT06464367Phase 1Recruiting
- Sponsor
- Yale University
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised trial of psilocybin in migraine (4 arms), sponsored by Yale University. Primary endpoints: Baseline SV2A PET up to 6 months, Baseline Resting State Functional Connectivity up to 6 months and 2 more. Started May 2025; status: recruiting.
02
Drugs
psilocybin
03
Conditions
migraine
Beyond the preview
Go deeper on NCT06464367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06464367.